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ScienceDirectHIV cure is impeded by the persistence of a strenuous reservoir
of latent but replication competent infected cells, which remain
unsusceptible to c-ART and unrecognized by the immune
system for elimination. Ongoing progress in understanding the
molecular mechanisms that control HIV transcription and
latency has led to the development of strategies to either
permanently inactivate the latent HIV infected reservoir of cells
or to stimulate the virus to emerge out of latency, coupled to
either induction of death in the infected reactivated cell or its
clearance by the immune system. This review focuses on the
currently explored and non-exclusive pharmacological
strategies and their molecular targets that 1. stimulate reversal
of HIV latency in infected cells by targeting distinct steps in the
HIV-1 gene expression cycle, 2. exploit mechanisms that
promote cell death and apoptosis to render the infected cell
harboring reactivated virus more susceptible to death and/or
elimination by the immune system, and 3. permanently
inactivate any remaining latently infected cells such that c-ART
can be safely discontinued.
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Introduction
Millions worldwide are infected with HIV and depend on
daily antiretrovirals for survival. Combination antiretroviral
therapy (cART) suppresses HIV replication and halts dis-
ease progression. However, a small reservoir of replication-
competent virus lingers in long-lived resting memory CD4
+T cells, which, because the virus is in a latent state, are not
targeted by cART [1]. Persistence of these cells leads towww.sciencedirect.com inevitable rebound of viral replication once cART is inter-
rupted and constitutes a roadblock to cure. Viable HIV cure
dictates either elimination of the latent reservoir or its
permanent containment such that cART can be safely
discontinued. Ongoing progress in molecular understand-
ing of HIV latency has led to development of pharmaco-
logical strategies that target the latent HIV infected cell
reservoir (Figure 1). While ‘block and lock’ [2] relies on
permanent suppression of latent virus, other approaches
aim to reverse HIV-1 latency in infected cells via latency
reversal agents (LRAs) [3] such that either cell death is
induced, or HIV infected cells are ‘seen’ and eliminated by
an immune response. This review focuses on the arsenal of
pharmacological agents and mechanisms they exploit to
target the reservoir for latency reversal, permanent inacti-
vation, and/or cell death. Other important strategies not
discussed include the breadth of interventions to boost
HIV-specific immunity for viral elimination [4–7].
Pipeline of latency reversal agents (LRAs)
Following integration, transcription at the proviral pro-
moter or 50 long terminal repeat (50LTR) is controlled by
the host transcription machinery and influenced by sur-
rounding chromatin landscape [8]. Regardless of genomic
position,50LTRlatent structure isdefined by Nucleosome-
0 (Nuc0) connected by a stretch of accessible DNA (HSS1)
to the strictly positioned repressive Nuc1 downstream of
the transcription start site (TSS), which is remodeled upon
activation (Figure 2a) [8,12,15]. HIV-1 transcription is
initiated by engagement of inducible sequence-specific
transcription factors (TFs) and associated cofactors at the
50LTR, controlling accessibility to RNA Polymerase II (Pol
II) and permissiveness to transcription (Figure 2). Under
basal conditions transcription is initiated but Pol II pauses,
producing short transcripts [9,12,15]. The HIV transacti-
vator Tat, a major determinant of reactivation from latency,
when expressed, recruits the positive transcription elonga-
tion factor (PTEFb) to the nascent TAR RNA, releases Pol
II pausing, activating transcription elongation [8,12,15].
HIV-1 expression is also restricted post-transcriptionally
via previously underappreciated mechanisms that can also
be explored pharmacologically to modulate latency [10,11].
De-repressors: pharmacological interventions that
counter repressive chromatin
Targeting PTMs
A broad category of LRAs affect post-translational mod-
ifications (PTMs) of N-terminal histone tails, modulatingCurrent Opinion in Virology 2019, 38:37–53
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Pharmacological strategies to target the latent HIV-1 reservoir. (a) The inducible fraction of the HIV-1 latent reservoir is ‘shocked’ with LRAs to
induce expression of the provirus. (b) Cells expressing viral particles die due to the associated cytotoxicity and via pharmacological interventions
that sensitize HIV reactivated cells toward cell death. (c) Reactivated cells are also recognized and killed by the immune system which can be
strengthened and boosted via a number of strategies including small molecule checkpoint inhibitors that enhance T cell function, bi/tri-specific T
cell engagers (BI/TRIES) and dual-affinity re-targeting proteins (DARTs). (d) In case of inefficient activation and insufficient clearance of latently
infected cells, a deeper state of latency is pharmacologically promoted in the remaining fraction of the reservoir (‘block and lock’). (e) Efficient
‘block and lock’ strategies, capable of driving the whole reservoir into a deep latency state, could also, in principle, be used alone without the
need of additional interventions.the strength of DNA-nucleosomal core interaction and
can serve as marks for recruitment of protein complexes
that regulate chromatin structure [12,13]. The best-char-
acterized modification, histone acetylation is deposited
by histone acetyltransferases (HATs) and removed by
histone deacetylases (HDACs), which are associated with
the latent HIV-1 promoter and can be targeted with
HDAC inhibitors (HDACis) for derepression [13]. The
repressed HIV-1 promoter is also characterized by
latency-associated H3K27me3, deposited by polycomb
group repressive complex 2 (PRC2) histone methyltrans-
ferase (HMT) EZH2, and serves as a mark to recruit other
repressors including HDACs, PRC1 and DNA methyl-
transferases (DNMTs) [14–16]. As well, heterochromatin
associated HMTs G9a and Suv39H1-deposited H3K9di/
tri-methyl marks [14–16] occupy the latent LTR. A
previously underappreciated modification, H4K3 Croto-
nylation, found to be associated with latency reversal, can
be enhanced by sodium crotonate as substrate [17].
HDACis Romidepsin, Panobinostat, Vorinostat, and Val-
proic acid have been extensively studied for their latency
reversal potential [18–21]. The metabolite acetate, highly
concentrated in the gut and blood, inhibits HDAC
activity and boosted HIV replication [22]. Clinical trialsCurrent Opinion in Virology 2019, 38:37–53 and in vitro data have confirmed their sufficient clinical
tolerance and effectiveness as LRAs that mechanisti-
cally enhance transcriptional noise and synergize with
signal-dependent HIV-1 activation [23,8], inducing
viral RNA and protein [24]. But clinically, no significant
reservoir depletion with HDACis has been observed
[18–22]. A multitude of HDACis, targeting all or spe-
cific HDAC classes have been developed (Table 1 ).
Class I appear to play a prominent role in latency with
Class I HDACis inducing stronger HIV-1 derepression
[25,26]. A recent comparison of HDACis pointed to
benzamide moiety and pyridyl cap group molecules,
such as Chidamide to be most active with least associ-
ated cytoxicity [27].
HMTis. The potential of HMTIs as LRAs has more
recently emerged. Inhibition of SUV39H1 with Chae-
tocin, or targeting G9a with the quinazoline BIX-01294
and more recently UNC-0638, a BIX-01294 derivative
with better toxicity profile, reversed latency in CD4+T
cells of suppressed patients [14–16,28]. H4K20 mono-
methylation, deposited by SMYD2, was linked to HIV-1
latency and its inhibition by AZ391 led to increased cell
associated HIV-1 RNA in c-ART treated patient CD4+T
cells [29]. Wide spectrum EZH2 HMTis includingwww.sciencedirect.com
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Figure 2
Distinct steps in control of the HIV-1 LTR transcription cycle represented in the latent and active states, simplified overview. (a) The chromatin
architecture of the HIV-1 promoter consists of three strictly positioned nucleosomes (Nuc-0, Nuc-1 and Nuc-2) separated by nucleosome free
regions. In the repressed state (left panel), the BAF complex is recruited to the LTR tethered by BRD4S and mediates the positioning of the
repressive Nuc-1, downstream of the transcriptional start site (TSS). The latent HIV-1 promoter is also characterized by the presence of repressive
cofactors, including HDACs, HMTs and the NuRD complex. (b) Upon signal-dependent activation, sequence-specific TFs bind their consensus
sites at the HIV-1 50 LTR and mediate the recruitment of RNA Pol II, required for transcription initiation, and HATs, rendering the chromatin more
permissive to transcription. (c) In basal conditions RNA Pol II processivity is restricted by the activity of negative elongation factors NELF and
DSIF which promote the early dissociation of RNA Pol II from the DNA template, and inhibit the production of full length viral RNAs. Additionally,
the availability of P-TEFb is restricted by sequestration within the 7SK snRNP complex and by BRD4-dependent chromatin recruitment.
Productive infection requires sufficient expression of the viral transactivator Tat that dramatically potentiates transcription elongation. Tat binds
TAR, a hairpin loop RNA structure of the nascent transcript, and recruits P-TEFb to the 50 LTR. Within P-TEFb, the kinase activity of CDK9
promotes phosphorylation of NELF, DSIF and the RNA Pol II CTD, hence increasing RNA Pol II processivity. Tat PTMs modulates its association
with cellular cofactors including HATs and PBAF, remodeling chromatin and enhancing transcription.DZNep reactivated latent HIV in cell lines, although
with substantial toxicity, while recently, specific EZH2
inhibitors EPZ-6438, GSK-343 more effectively
reversed latency in resting CD4+T cells from infected
individuals [14–16,28].www.sciencedirect.com DNMTis. HIV 50LTR CpG methylation promotes bind-
ing of methyl–CpG-binding protein (MBD2) and recruit-
ment of the repressive NuRD complex [8]. While the
importance of this mechanism in vivo has been ques-
tioned [8,12,15], sequential treatment with DNMTis andCurrent Opinion in Virology 2019, 38:37–53
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Table 1
Pharmacologic interventions to target the latent HIV-1 reservoir
Class Subclass Function/Target Compounds Experimental system References (Fully listed in
reference list)
Chromatin
modulators
ACSS2 agonist Sodium crotonate (Na-Cro) A, F Jiang et al., 2018
Histone methyl
transferases inhibitors
(HMTis)
HMT (SMYD2 inhibitor) AZ391 A, F Boehm et al., 2017
HMT (G9a inhibitor)
BIX-01294 A Imai et al., 2010
UNC-0638 D, F Nguyen et al., 2017
Polycomb (L3MBTL1
inhibitor)
UNC-926 A, F Boehm et al., 2017
Polycomb (SUV39H1
inhibitor)
Chaetocin A Bernhard et al., 2011
Polycomb (EZH1/EZH2
inhibitor)
UNC-1999 D Kobayashi et al., 2017
Polycomb (EZH2 inhibitor)
3-deazaneplanocin A (DZNep) A Friedman et al., 2011
EPZ-6438; GSK-343 A, F Nguyen et al., 2017
Histone deacetylases
inhibitors (HDACis)
HDAC Class I
CG05; CG06 A Choi et al., 2010
Thiophenyl benzamide (TPB) A, F Huang et al., 2018
Chidamide A, F, G (NCT02902185,
NCT02513901)
Yang et al., 2018
Entinostat A, F Wightman et al., 2013
Largazoles (SDL148; JMF1080;
SDL256)
A, D Albert et al., 2017
Mocetinostat C Zaikos et al., 2018
Romidepsin D; G (NCT02092116,
NCT01933594,
NCT02850016,
NCT03041012,
NCT03619278,
NCT02616874,
NCT01933594)
Wei et al., 2014
Pimelic diphenylamide 106,
Pyroxamide
D Kobayashi et al., 2017
HDAC3/6 Apicidin A Lin et al., 2011
HDAC3 BRD3308 A, F Barton et al., 2014
HDAC3/6/8 Droxinostat
(pan)HDAC
Belinostat A Matalon et al., 2011
Givinostat A Matalon et al., 2010
KD5170, Pracinostat (SB939) D Kobayashi et al., 2017
M344 A Ying et al., 2012
Metacept-1; Metacept-2;
Oxamflatin
A Shehu-Xhilaga et al., 2009
Panobinostat F, G (NCT02471430,
NCT01680094)
Bullen et al., 2014
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Table 1 (Continued )
Class Subclass Function/Target Compounds Experimental system References (Fully listed in
reference list)
Chromatin
modulators
Histone deacetylases
inhibitors (HDACis)
(pan)HDAC
Psammaplin A A, E Richard K et al., 2018
Scrpitaid A Ying et al., 2010
Sodium butyrate (Na-But) A Reuse et al., 2009
ST7612AA1 E Badia et al., 2015
Trichostatin A (TSA); Trapoxin A
(TPX)
A Van Lint et al., 1996
Valproic Acid (VPA) G (NCT03525730,
NCT00614458)
Lehrman et al., 2005
Vorinostat (SAHA) D, F, G (NCT02336074,
NCT03198559,
NCT03803605,
NCT03212989,
NCT03382834,
NCT02475915,
NCT02707900,
NCT01319383)
Contreras et al., 2009
SIRT2 inhibitor AGK2 D Kobayashi et al., 2017
HDACI/II acetate E Bolduc et al., 2017
BRG-1-associated factors
complex inhibitors (BAFis)
BAF complex CAPE; MGD-486;
Pyrimethamine
D, F, G (NCT03525730) Stoszko et al., 2016
ARID1A subunit of BAF Macrolactams D, F Marian et al., 2018
DNA methyltransferases
inhibitors (DNMTis)
Decitabine (5-aza-20-
deoxycytidine)
A, D Kauder et al., 2009
Zebularine A, F Blazkova et al., 2009
Activators of
Transcription
Extracellular stimulators
CD122/CD132 ALT-803 (IL-15 superagonist
complex)
D, E (NCT02191098) Jones et al., 2016
CD122/CD132 IL-2, Il-6, TNFa F, G (NCT03382834) Tae-Wook Chun et al., 1998
CD127/CD132 CYT107 (recombinant IL-7) F, G (NCT01019551) Wang et al., J 2005; Katlama
et al., 2016
CD28 aCD28 A, D Tong-Starkesen et al., 1989;
Spina et al., 2013
Surface glycans rGal9 (recombinant Gal9) A, F Abdel-Mohsen et al., 2016
Phytohemagglutinin (PHA) A, D Spina et al., 2013
EGFR inhibitor AG555 A Calvanese et al., 2013
TCR agonist aCD3 A, D Spina et al., 2013
S1P1 S1P1 agonists C, Duquenne et al., 2017
aPD1 antibodies Pembrolizumab E, G (NCT02595866,
NCT03239899)
Fromentin et al., 2019
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Table 1 (Continued )
Class Subclass Function/Target Compounds Experimental system References (Fully listed in
reference list)
Activators of
transcription
Protein kinase C agonists
(PKC agonists)
12-deoxyphorbol 13-
phenylacetate (DPP)
A Bocklandt et al., 2003
3-(2-Naphthoyl)ingenol A Liu et al., 2018
Aplysiatoxin;
Debromoaplysiatoxin
A, E Richard et al., 2018
Bryologs A, D Marsden et al., 2018
Bryostatin-1 G (NCT02269605) Gutie´rrez et al., 2016
C3-esterified ingenol derivatives A, F Spivak et al., 2018
EK-16A A, F Wang et al., 2017
Euphoria Kansui extract D, E, G (NCT02531295) Cary et al., 2016
Gnidimacrin A, E Huang et al., 2011; Lai et al.,
2015
IDB (ingenol 3, 20-dibenzoate) F Spivak et al., 2015
Ingenol-B (ingenol-3-
hexanoate)
D, F Jiang et al., 2014; Pandelo´
Jose´ et al., 2014
LMC03; LMC07 F Hamer et al., 2003
Namushen-1; Namushen-2 A Tietjen et al., 2018
PEP005 (ingenol-3- angelate) A, F, Jiang et al., 2015
Phorbol 12-myristate 13-acetate
(PMA)
A, D Folks et al., 1988; Spina
et al., 2013
Prostratin A, E Gulatosky et al., 1997;
Kulkosky et al., 2001
Sesterterpenoids A Wang et al., 2016
SJ23B A Bedoya et al., 2009
Toll-like receptor agonists
TLR1/2 Pam2CSK4, Pam3CSK4;
Imiquimod
D, E Novis et al., 2013, Macedo
et al., 2018
TLR2 HKLM A Alvarez-Carbonell et al.,
2017
PIM6 D Rodriguez et al., 2013
TLR3 Poly-ICLC A, G (NCT02071095) Alvarez-Carbonell et al.,
2017
TLR2/7 CL413 D, E Macedo et al., 2018
TLR5 Flagellin A Thibault et al., 2009
TLR7/8 R-848 A, C (productive infection) Schlaepfer et al., 2006
TLR7
vesatolimod (GS- 9620) E, G (NCT03060447,
NCT02858401)
Tsai et al., 2017
GS-986 H Lim et al., 2018
TLR8 3M-002 A, F Schlaepfer and Speck, J,
2011; Rochat et al., 2017
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Table 1 (Continued )
Class Subclass Function/Target Compounds Experimental system References (Fully listed in
reference list)
Activators of
transcription
Toll-like receptor agonists TLR9
CPG-7909 G (NCT00562939) Winckelmann et al., 2013
MGN1703 A, E, G (NCT02443935) Offersen et al., 2016
CpG oligonucleotides: ODN-
2006; ODN-2040
A Scheller et al., 2004
Activators of transcription
factors
NF-kB - CCR5 Maraviroc D, G (NCT02486510,
NCT02475915,
NCT00935480,
NCT00808002)
Lo´pez-Huertas et al., 2017;
Madrid-Elena et al., 2018
NF-kB Juglone (5HN) A, D Yang et al., 2009
NF-kB and MSK1 activation Cocaine A Sahu et al., 2015
NF-kB activation As2O3 (Aresenic trioxide; FDA-
approved drug)
A Wang et al., 2013
STAT5 sumoylation
inhibitors
Benzotriazoles (HODHBt, HBt,
HOBt, HOAt)
F Bosque et al., 2017
NFAT activator AV6 D Micheva-Viteva et al., 2011
RUNX1 inhibitor Ro5-3335 E Klase et al., 2014
SRC agonist MCB-613 A, B Nikolai et al., 2017 (8th HIV
Persistence during Therapy
Workshop)
HSF-1 stimulators Resveratrol; Triacetyl resveratrol A Pan et al., 2016; Zeng et al.,
2017
PTEN dysregulation Disulfiram D, G (NCT03198559;
NCT01286259;
NCT01944371,
NCT01571466)
Elliott et al., HIV 2015; Spivak
et al., 2014
PKA agonist Bucladesine (dibutyryl-cAMP) A Lin et al., 2018
PI3K agonist Oxoglaucine (57704) A, E Doyon et al., 2014
Heme oxygenase-1 agonist Heme arginate A Shankaran et al., 2011
GSK3 inhibitors SB-216763; Tideglusib F Gramatica et al., 2017 (8th
HIV Persistence during
Therapy Workshop)
GADD34 / PP1 inhibitor Salubrinal A, F Pan et al., 2016
Calcineurin agonist Ionomycin A, D Siekevitz et al., 1988; Spina
et al., 2013
BTK inhibitor Terreic acid A Calvanese et al., 2013
Sp1 Hydroxyurea A Oguariri et al., 2007
Inhibitors of apoptosis
(IAPs)
BIRC2
Debio 1143 B, F Bobardt, Kuo, Gallay, 2019
Birinapant; SBI-0637142; LCL-
161
F Pache et al., 2015
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Table 1 (Continued )
Class Subclass Function/Target Compounds Experimental system References (Fully listed in
reference list)
Transcription
elongation
control
Inhibition of BET
KAT5 inhibitor MG-149 D, F Li et al., 2018
BET inhibitors
8-methoxy-6- methylquinolin-4-
ol (MMQO)
D, E Abner et al., 2018;
Gallastegui et al., 2012
Apabetalone (RVX-208), PFI-1 A, F Lu et al., 2017
I-BET; I-BET-151; MS-417 A, D Nilsson et al., 2016
JQ1 D, F Banerjee et al., 2012
OTX-015 A, F Lu et al., 2016
UMB-136 D, F Huang et al., 2017
Hexamethylene bisacetamide
(HMBA)
C, F Vlach and Pitha, 1993;
Klichko et al., 2005
7SK snRNP
HEXIM HMBA A C, D Contreras et al., 2009; Spina
et al., Pathogens 2013
7SK RNA Gliotoxin D, F Stoszko et al., 8th HIV
Persistence during therapy
workshop, Miami 2017
Tat TAR-LTR
TatR5M4 A, D, F Geng et al., 2016
EXO-Tat A, D, F Tang et al., 2018
Immune checkpoint inhibitors
Durvalumab (anti-PD1) G NCT03094286
Cemiplimab (anti-PD1) G NCT03787095
Nivolumab (anti-PD1) G NCT02408861
BMS-936559 (anti-PD1) G NCT02028403
Pembrolizumab F, G case study, N = 1 Fromentin et al., 2019,
NCT02595866
Ipilimumab (anti- CTLA-4) E (case study, N = 1); G
(NCT02408861,
NCT03407105)
Wightman et al., 2015
Post transcriptional control SF3B1 inhibitor sudemycin D6 A, D Kyei et al., 2018
SR protein family: SRp20/
SRSF3
Digoxin C, E Wong et al., 2013
Cardiac glycoside/aglycones A, C, E Wong et al., 2018
SR protein family: SF-2 DHA-type compound 9 (1C8) A Cheung et al., 2016
Rev-RRE formation
Clomifene A Prado et al. 2016
8-Azaguanine, 2-(2-[5-Nitro-2-
thienyl]vinyl)quinolone
C, E Wong et al., 2013
CRM1 inhibitors
LMB, ratjadone A A Fleta-Soriano et al., 2014
PKF050-638 A Daelemans et al., 2002
CBC inhibitor ABX464 D, G (NCT02735863,
NCT02990325)
Vautrin et al., 2019; Steens
et al., 2017
Miscellaneous Deoxyhypusyl hydroxylase Deferiprone C, G (NCT02191657) Saxena et al., 2016
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Table 1 (Continued )
Class Subclass Function/Target Compounds Experimental system References (Fully listed in
reference list)
Miscellaneous Adenosine reuptake inhibitor Dilazep A Calvanese et al., 2013
Proteasome inhibitors
Carfilzomib (CFZ) A, F Pan et al., JBC 2016
MG-132 (ONX-0914/PR-957);
Velcade; CLBL
A, D Miller et al., 2013
PR-957 (ONX-0914/MG-132) A, F Li et al., 2018
Unknown
Abyssomicin-2 D, F Leon et al., 2015
HHODC A, E Kapewangolo et al., 2017
Piceatannol A Elbezanti et al., 2017 (oral
presentation); Zeng et al.,
JAFC 2017
PH01; PH02; PH03; PH04; PH05 A, F Hashemi et al., 2018
Quinolin-8-ol derivatives A, D Xing et al., J 2011
Radicicol; Pochonin B; Pochonin
C
D Mejia et al., J 2014
Block and Lock approaches Kinase inhibitors Danusertib, PF-3758309 D Vargas et al., 2018
mTOR inhibitors Torin1, pp242 and rapamycin
(Sirolimus)
F, G (NCT02440789) Besnard et al., 2017
Tat inhibitor
Didehydro-cortistatin A (dCA) A, B, F Mosseau et al., 2015;
Kessing et al., 2017
Triptolide wilfordii A, G (NCT02219672) Wan and Chen, 2014
JAK-STAT inhibitors Tofacitinib and ruxolitinib D, F Gavegnano et al., 2017
LEDGF/p75 inhibitors LEDGINs D Vranckx et al., 2016
FACT complex, elongation curaxin 100 (CBL0100) D, E Jean et al., 2017
Inhibition of NFKB activation,
through Hsp90 inhibition
GV1001 A Kim et al., 2016
calcineurin inhibitor cyclosporin A A, D Chan et al., 2013
CDK9 inhibitors
F07#13 B Van Duyne et al., 2013
FIT-039 A Okamoto et al., 2015
Panel of inhibitors A Nemeth et al., 2011
2-fluorophenyl (12 d), flavopiridol
analogue
A Ali et al., 2009
PKC Benzolactam derivative, BL-V8-
310
A, E Matsuda et al., 2019
Induction of cell death BET inhibitor Apabetalone A, F Xuan-xuan Zhang et al., 2019
Bcl-2 agonists Venetoclax, Navitoclax F Campbell et al., 2015, CROI,
conference
PI3K/Akt inhibitors Edelfosine, Perifosine,
Miltefosine
A Lucas et al., 2010
Lancemaside A, Compound K,
Arctigenin
A Kim et al., 2016
Induction of cell death
SMAC mimetics
Birinapant, GDC- 0152, Embelin F Campbell et al., 2018,
Hattori, 2018
AZD5582; AT406; BV6; SM164;
GDC0152
A, F Sampey et al., 2018
SM-AEG40730, SM-LCL161 A, C Ashok Kumar et al., 2019
RIG-I Acitretin F Li et al., 2016; Garcia-Vidal
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Current Opinion in Virology 2019, 38:37–53 HDACis synergized to reactivate HIV-1 in cART treated
patient cells [30].
Targeting chromatin structure
A major determinant of HIV latency, chromatin, is
restructured by the activity of ATP-dependent remode-
lers. The CHD3 containing NuRD remodeller and
related CHD1 repress HIV-1 [8,9]. The INI-1 containing
ATP-dependent BAF remodeller is associated with the
50LTR and represses HIV-1 by actively positioning Nuc-
1 [8]. Interestingly, BRD4S, a short isoform of the bro-
modomain protein BRD4, tethers BAF to the 50LTR,
silencing HIV-1 [31]. Such enforced chromatin structure
represents a mechanical block for HIV-1 transcription,
subject to pharmacological intervention for reversal
[8,31,32,33,34].
BAF inhibitors (BAFis). Small molecule BAFis re-acti-
vated latent HIV-1 in a spectrum of in vitro latency
models and in c-ART suppressed HIV-1 infected patient
CD4+T cells [32]. BAFis CAPE and Pyrimethamine
enhance transcriptional noise [34]. When combined with
PKC agonists showed significantly increased potency
than single treatments, pointing, similar to HDACis, to
their potential in combinatorial LRA approaches.
Recently, a screen of almost 350 000 compounds led to
identification of ARID1A targeting macrolactam scaffold
BAFis, which reversed HIV-1 latency in primary CD4+T
cells with limited cytoxicity, representing promising
LRAs for clinical investigation [33].
BET inhibitors (BETis), in addition to enhancing HIV-1
transcription elongation (Section ‘Enhancing HIV-1 tran-
scriptional elongation’), act as derepressors of HIV-1
transcription in a Tat independent manner [8]. BETis
inhibited 50LTR-bound BRD2, and BRD4S, inducing
LTR chromatin derepression in a BAF-dependent man-
ner [8,31]. Small molecule BETis are under develop-
ment with differing potency and specificity to circumvent
clinical limitations of JQ1 (Table 1).
Inducing HIV-1 transcription activation
The 50LTR contains a plethora of consensus sequences for
TFs whose binding leads to HIV-1 50LTR recruitment of
Pol II and basal TFs [8,12,15] (Figure 2b). NF-kB/p65,
arguably the strongest activator of HIV-1 transcription
initiation, and molecular effectors that facilitate its bind-
ing such as those in the protein kinase C (PKC), TLR,
and TNFa signaling pathways, are high potential phar-
macological targets for latency reversal [9,35]. AP-1,
STAT5 and NFAT are also among important HIV-1
transcription activators [8,9,36].
Targeting NFkB
In latent HIV-1 infected resting CD4+T cells, p65 is
sequestered in the cytoplasm while the 50LTR is
repressed by p50 homodimers. Upon canonical NFkBwww.sciencedirect.com
Broad drug arsenal to attack a strenuous latent HIV reservoir Stoszko et al. 47activation, p65 translocates to the nucleus, binds 50LTR
as a p65/p50 heterodimer and recruits Pol II, HATs, as
well as PTEFb, leading to initiation and elongation of
HIV transcription [8,9,35]. While an attractive pathway
for LRA-based interventions, NFkB signaling is a master
regulator of immune and other functions and its pharma-
cological modulation exposes risks of serious side effects
[35]. Interestingly, small molecule mimetics of mitochon-
dria-derived activator of caspases (SMAC mimetics) (Sec-
tion ‘Inhibitors of IAPs’), activated non-canonical NF-kB
and binding of RELB/p52 heterodimers to the 50LTR
resulting in latency reversal (Table 1) without causing T
cell activation, pointing to non-canonical NFkB as an
interesting avenue for further exploration [27,37,38].
PKC agonists. A spectrum of drugs targeting the PKC
pathway, including Prostratin, Bryostatin-1 and Ingenols
activate NFAT, NFkB and AP-1 binding to the 50LTR
(Table 1), leading to strong proviral transcription initia-
tion [18,39–45]. While PKCa and PKCu stimulation
targets HIV-1 [46], most currently available PKC agonists
target many PKC isoforms resulting in pleiotropic and
consequent toxic effects, highlighting need for novel
more specific PKC agonists [18,45,46].
Maraviroc, a CCR5 antagonist HIV entry blocker was
shown to also reverse latency via NFkB activation [47,48].
Maraviroc induced NFkB phosphorylation and HIV tran-
scription as shown by increased cell associated HIV-1
RNA in patient CD4+ T cells [48]. Maraviroc is attractive
for inclusion in pharmacological LRA strategies because
of its mechanistic versatility as an LRA and antiviral.
TLR agonists have gained much attention due to their
multifactorial effects on the HIV-1 reservoir [49,50–54].
At least ten TLRs are described that function as first line
of pathogen recognition and induce innate and adaptive
immune defenses. Dual TLR agonists such as CL413
showed potent HIV-1 reactivation via complementary
targeting of TLR2 and TLR7, leading to NFkB activa-
tion concomitant with TNFa production [49].
MGN1703, a TLR9 agonist induced HIV plasma RNA
in 6 of 15 study participants concomitant with increased
activation of NK and CD8+T cells, although no reduction
in latent reservoir was observed [50]. The TLR7 agonists
GS-986 and GS-9620, suggested to also enhance anti-HIV
immune effector function, reversed latency in patient
cells [51]. These TLR7 agonists also increased plasma
HIV-1 RNA concominant with decreased HIV-1 DNA in
the infected rhesus model, where two of nine animals
have remained aviremic [52]. Because of this functional
versatility, TLR agonists show much promise in reservoir
elimination strategies.
Other TFs
LRAs can reduce or enhance HIV-1 50LTR binding of
repressive/activating TFs [8,12,15]. Resveratrolwww.sciencedirect.com promotes histone acetylation and activation of HSF1,
an HIV-1 transcription activator [55]. Benzotriazoles
were recently shown to stabilize the active form of
STAT5 and reactivate HIV-1 [36].
Enhancing HIV-1 transcriptional elongation
Inefficient transcription elongation via promoter-proxi-
mal Pol II 50LTR pausing is a major rate-limiting step in
latency reversal [56] (Figure 2c), which is released by
Tat; when expressed at sufficient levels, Tat orchestrates
a strong positive transcriptional feedback loop [8]. Tat
binds TAR and recruits PTEFb, whose CDK9 compo-
nent phosphorylates the Pol II C-terminal domain (CTD)
as well as NELF and DSIF (which promote Pol II
dissociation when unphosphorylated), enhancing Pol II
processivity. In latent cells, PTEFb is predominantly
sequestered within the 7SKsnRNP complex, a ribonu-
cleoprotein scaffold in which PTEFb activity is inhibited
[8]. Tat also competes for PTEFb with BRD4, which
binds and sequesters PTEFb [9]. To enhance transcrip-
tion elongation, in addition to PTEFb, Tat recruits a
number of other interactors, including chromatin modi-
fiers, whose binding is regulated by deposition and
removal of PTMs and these can also be exploited pharma-
cologically [8,57–59].
BETis. Inhibition of BRD4 releases PTEFb, increasing
its availability for binding Tat. BETis activate latent HIV
in a spectrum of latency models and after treatment of
cells from HIV infected patients [60–63] (Table 1).
Interestingly, inhibition of the lysine acetyltransferase
KAT5 reduced 50LTR histone H4 acetylation and
impaired BRD4 recruitment, similar to BETis, resulting
in increased PTEFb pool for Tat reactivation of latent
HIV-1 [64]. Thus BETis are promising LRAs that act via
a dual mechanism, relieving BRD4S-BAF-mediated
LTR repression as well as increasing availability of
PTEFb for Tat.
Compounds disrupting 7SK snRNP. In resting CD4+T
cells the majority of PTEFb is sequestered in an inactive
form within the 7SK snRNP complex [8]. Inhibition of
the HEXIM subunit of 7SK snRNP by HMBA enhanced
PTEFb activity and latency reversal [9,63,65]. We
recently found Gliotoxin, a small molecule secreted by
Aspergillus fumigatus reversed latency in HIV infected
patient CD4+T cells by disrupting 7SK snRNP causing
PTEFb release and transcription elongation at the HIV
LTR (submitted).
Tat has remarkable specificity for the HIV 50LTR and can
penetrate cell membranes. In an attenuated form [66], or
exosomally delivered [67], Tat activated HIV-1 in CD4
+T cells obtained from c-ART suppressed infected indi-
viduals and significantly increased the potency of other
LRAs. The potential of Tat as a therapeutic vaccineCurrent Opinion in Virology 2019, 38:37–53
48 Engineering for viral resistancecandidate has also been explored [68] and may play a role
in efforts toward reservoir depletion.
Immune checkpoint (IC) blockers. PD-1 has been sug-
gested to confer persistence of HIV-1 latency during c-
ART, likely via inhibition of signaling pathways that lead
to PTEFb activity [69,70]. IC blockers reversed latency
in cells obtained from suppressed patients [71], although
another study found less robust effects [72]. Further
investigation will determine effectiveness of IC blockers
as LRAs and/or in alleviating CD8+T cell exhaustion.
Targeting post transcriptional regulation
Viral proteins were shown to be produced in a small
fraction of LRA-reactivated cells which transcribed viral
RNA [73]. This points to the presence of post-transcrip-
tional blocks in viral reactivation [56], where HIV-1
RNA is subjected to splicing and polyadenylation and
RNA surveillance proteins influence viral RNA metabo-
lism. Lack of polyadenylated mRNA compromises tran-
script stability, export and HIV-1 protein production
while block in splicing decreases HIV-1 expression
[10,11,56,74–77]. The significant contribution of post-
transcriptional and transcription elongation blocks to effi-
cient HIV latency reversal have only recently come to
light. Although these regulatory mechanisms have not
been extensively explored in the context of HIV reacti-
vation, effective latency reversal may require interven-
tions that improve viral RNA stability, splicing, export
and translation in order to boost viral protein production.
Pipeline of block and lock agents
On the flip side of reversing latency as a stepping stone to
viral elimination, ‘block and lock’ [2] is a functional cure
strategy to permanently shut down viral expression, elim-
inating the need for continued antiviral therapy.
Tat inhibition
The HIV-1 Tat inhibitor Didehydro-Cortistatin A (dCA)
binds Tat and effectively disrupts Tat/TAR axis [78],
restricting HIV-1 transcription and replication. dCA treat-
ment was shown to restrict PBAF recruitment while
enhancing BAF 5’LTR occupancy and Nuc-1 mediated
repression [79]. Consistently, ex vivo dCA treatment of
CD4+T cells from HIV-1 infected individuals both
improved c-ART suppression of infection and led to
strengthened 50LTR chromatin and epigenetic repres-
sion, restricting viral reactivation in latently infected cells
and leading to a delayed viral rebound after c-ART
interruption [2].
Targeting host factors to reinforce latency
In line with block and lock, compounds targeting host
factors DDX3, DDX5, Matrin3, Mov10, splicing factors,
UPF proteins, involved in HIV-1 post-transcriptional
processing, including inhibitors of mTOR, cardiotonic
steroids, SR proteins, inhibit HIV-1 latency reversalCurrent Opinion in Virology 2019, 38:37–53 and lead to a block in translation [74–81]. Inhibition of
HIV-1 Rev and Rev response element (RRE) association
on the viral RNA or the cellular factor CRM1 can block
nuclear export of unspliced viral mRNA [82]. ABX464-
mediated inhibition of the cap binding complex increased
viral splicing, halting production of unspliced RNA
required for viral assembly [83]. LEDGINs, molecules
that inhibit HIV-1 integrase-LEDGF interaction were
described to shift preferential sites of HIV-1 integration
out of active transcription units, and retarget HIV into
regions refractory to reactivation [84]. Block and lock
strategies, similarly to LRAs, can in principle work most
effectively in combination; dCA, LEDGINs, compounds
that strengthen proviral epigenetic repression, and ulti-
mately modulators of splicing and viral export, may act
synergistically to induce a deeper state of latency to delay
or permanently suppress viral rebound.
Inducing cell death
An attractive approach to eliminate HIV-1 emerging out
of latency is to pharmacologically target danger sensing,
stress and apoptotic pathways in order to induce cell
death in LRA-reactivated HIV expressing cells [85]. This
would bypass necessity for an anti-HIV immune response
to eliminate reactivated cells. To this end, coupling LRA-
induced HIV activation with inhibitors of inhibitors of
apoptosis (IAPs), stimulation of danger sensing pathways,
and indirect triggering of stress by blocking the cell’s
physiological processes have drawn much attention as a
way to eliminate latently infected cells.
Inhibitors of IAPs
SMAC mimetics (SMs), molecules which target cell sur-
vival factors XIAP and cIAP1/BIRC2 have shown much
promise as both LRAs that act through noncanonical
NFkB activation as well as compounds that induce apo-
ptosis in HIV-1 infected cells through proteasomal deg-
radation of IAPs. SMs SBI-0637142 and LCL161 down-
regulated BIRC2/IAP, leading to proviral transcription
[37]. Debio 1143 targets BIRC2 for degradation inducing
non-canonical NFkB with subsequent HIV-1 latency
reversal in resting CD4+T cell from aviremic participants
[86]. SMs birinapant [38], GDC-0152, and embelin
induced apoptosis selectively in HIV-1 infected (but
not uninfected) central memory CD4+Tcells, leading
to their elimination [87]. Benzolactam related com-
pound BL-V8-310 induced apoptosis in HIV infected
cells reactivated in a PKC induced manner [44]. Interest-
ingly, in vitro treatment with the pro-apoptotic drug
Venetoclax, which blocks Bcl-2, followed by anti-CD3/
CD28 stimulation resulted in fast decay of productively
infected primary T cells in vitro and reduction of the
latent reservoir in vitro [88].
Stimulation of TLRs and RIG-I-like receptors (RLRs)
When latent HIV is reactivated, TLRs, RLRs and their
molecular effectors, act as sensors that trigger NFkB,www.sciencedirect.com
Broad drug arsenal to attack a strenuous latent HIV reservoir Stoszko et al. 49MAP kinase and interferon signaling and initiate an
innate immune response. Subsequent to detection of
viral RNA, RIG-1 induces apoptosis. Interestingly, reti-
noic acid (RA) induces expression of RIG-I and p300,
which in turn stimulates HIV-1. Acitretin a derivative of
RA reversed HIV-1 latency and induced apoptosis in
infected cells [89,90]. When combined with Vorinostat
even higher depletion of proviral DNA was observed. A
later study however challenged these findings showing
only weak latency reversal and cell death, pointing to
need for further evaluation. TLRs may also play multiple
roles, as LRAs, and mediators of HIV-infected cell death
[51,54]. A remaining question is whether and which
TLRs become activated by HIV-1 transcripts and pro-
teins upon latency reversal.
Combination, synergism and scalable therapy
Current LRAs reactivate only 5% of latently infected cells
[91], of which only an approximated 2–10% produce
viral protein in addition to expressing viral RNA [73].
Administration of certain LRA combinations in intervals,
rather than at once [19,30], stimulated higher proviral
expression, while sequential treatment rounds yieldedFigure 3
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www.sciencedirect.com new infecious particles. These observations point to a
limitation in potency of current LRAs as well as tran-
scriptional stochasticity of a diverse and strenuous latent
reservoir. The heterogeneous nature of molecular mech-
anisms controlling HIV latency predicts that a combina-
tion of compounds targeting distinct regulatory pathways
will be most effective to activate the reservoir. Synergistic
effects of LRAs have been shown ex vivo
[8,9,30,32,33,40,43,63]. While ongoing and future clinical
trials will shed more light on which mechanisms of
latency should be targeted in concert for most roboust
reversal, mechanistic and preclinical observations point to
combinations that include derepressors (eg. Vorinostat,
BAFis), activators of NFkB (eg. dual TLR agonists or
SMAC mimetics) and activators of transcription elonga-
tion (eg. BETis, Gliotoxin) to have high potential. The
use of LRAs in combination allows for lower concentra-
tions of each molecule to induce HIV activation. Hence,
combinatorial approaches emerge not only as a way to
improve the activation efficacy of individual LRAs, but
also as a way to govern a level of specificity towards HIV-1
latency reversal, limiting the pleiotropic and toxic effects
of each intervention (Figure 3).SUV39H1
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50 Engineering for viral resistanceIn contrast to antivirals, which target HIV, pharmacologi-
cal interventions to eliminate the HIV reservoir (Table 1),
with the exception of Tat and Tat and Rev-RRE inhi-
bitors, all target host molecular effectors, harbor inherent
pleiotropic effects and are subject to variability in
response. In this context, pharmacogenetics to investigate
the patient-specific response to distinct molecules may
identify robust treatments, which synergize at sufficient
magnitudes to overrule individual variability, paving the
way for scalable therapy options. Importantly, the com-
plex nature of the latent reservoir points to the likelihood
of future combinations of nonexclusive pipelines of
interventions. For example, potent latency reversal
and cell death promoting combination regimens could
be used, in presence of c-ART, to activate and eliminate
a more reactivatable fraction of the reservoir. Here
promoting clearance of latent cells via apoptosis and
immune boosting strategies could be used concomitantly
to improve reservoir elimination. Upon clearance of this
more labile latent reservoir, ‘block and lock’ regimens
may be employed to lock the remaining reservoir in a
permanently repressed state. A strengthened immune
system would then control the latent virus in case of
escape from the blocked state, in combination allowing
cessation of c-ART.
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